Radiopharm Theranostics - Positive trial data, Mar 15 2024:
Radiopharm Theranostics unveils promising data on RAD 301 and RAD 302 programs at the 2024 European Molecular Imaging Meeting. Succinylated gelatin shows superior kidney protection, enhancing the safety and efficacy of αvβ6-integrin targeted therapeutics for various cancers. Dr. Johannes Notni emphasizes the potential for RAD 302's clinical success based on these results.
Bristol Myers Squibb - FDA Approval, Mar 15 2024:
The FDA approved Breyanzi, a new cell therapy, for hard-to-treat blood cancers. Developed by Bristol Myers Squibb, it's for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who tried at least two other treatments. Breyanzi showed promising results, with around one in five patients seeing their cancer disappear completely, and 45% responding to the therapy. This approval offers new hope for those battling these tough cancers.
Full Article: https://www.biopharmadive.com/news/bristol-myers-breyanzi-cll-leukemia-fda-approval/710446/
Tubulis - Series B Investment, Mar 14 2024:
Tubulis has raised €128 million in a Series B2 financing round led by EQT Life Sciences and Nextech Invest, alongside other biotech investors. The funds will primarily support clinical evaluation of their lead solid tumor ADC candidates, TUB-030 and TUB-040, and expand their technology development into the US market. These candidates target significant antigens in solid tumors, with plans for clinical trials in 2024 and the establishment of a US subsidiary to enhance their global presence in ADC therapy.
Fusion Tx - Acquisition, March 19 2024:
Fusion Pharmaceuticals Inc. today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
Checkpoint Tx - Executive Changes, March 22 2024:
Checkpoint Therapeutics, Inc. today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.
Full Article: https://ir.checkpointtx.com/news-events/press-releases/detail/114/checkpoint-therapeutics-announces-appointment-of
Morphic - Executive Changes, March 19 2024:
Morphic Therapeutic today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics.
Full Article: https://investor.morphictx.com/news-releases/news-release-details/morphic-appoints-dr-simon-cooper-chief-medical-officer
Nouscom - Series C Investment, March 21 2024:
Nouscom secures $82 million in extended Series C financing, including $7.6 million from Angelini Ventures, to advance its cancer vaccine pipeline. Funds will support trials of NOUS-209 for metastatic colorectal cancer and Lynch Syndrome carriers, aiming to intercept, prevent, or delay cancer development.
Full Article: https://www.pharmaceutical-technology.com/news/nouscom-extends-series-c-round-to-82m-for-cancer-vaccine-trials/
Clasp Therapeutics - Series A Investment, March 20 2024:
Clasp Therapeutics, a newly launched biotechnology startup, secures $150 million in Series A financing led by Catalio Capital Management, Third Rock Ventures, and Novo Holdings to develop innovative dual-pronged cancer immunotherapies for challenging tumors. The company's focus on bispecific T-cell engagers aims to target tumors more precisely, potentially minimizing side effects associated with existing methods. With a strategy based on the work of renowned cancer researchers and significant financial backing, Clasp aims to advance its programs while prioritizing clinical data collection before considering public markets.
Full Article: https://www.biopharmadive.com/news/clasp-therapeutics-cancer-t-cell-bispecifics/710735/
Radiopharm Theranostics - Positive data release, March 15 2024:
Radiopharm Theranostics has unveiled positive data for its RAD 301 and RAD 302 programs at the 2024 European Molecular Imaging Meeting, showcasing the efficacy of targeting αvβ6-integrin in treating various carcinomas. The data, presented by Prof. Susanne Kossatz, highlights the substantial reduction of kidney uptake of αvβ6-integrin targeting therapeutics and diagnostics using succinylated gelatin, which triples the tumor-to-kidney ratio. Dr. Johannes Notni emphasizes the potential of this renal protection strategy to enhance the clinical success of RAD 302, particularly in cancers like pancreatic ductal adenocarcinoma, non-small cell lung cancer, and head-and-neck squamous cell carcinoma.
Tolremo - Executive Changes, Mar 21 2024:
TOLREMO has appointed Jeff Jonker and Mike Sherman, both seasoned veterans in the biotechnology industry, to its Board of Directors. With extensive experience in leadership, strategic planning, and financial management within the life sciences sector, Jonker and Sherman are poised to contribute significantly to TOLREMO's growth trajectory, particularly as the company advances its lead candidate, TT125-802, aimed at combatting transcriptional cancer drug resistance. Their appointments signal TOLREMO's commitment to leveraging expertise for operational execution and strategic advancement in its clinical-stage journey.
